BACKGROUND Although time-domain measures of heart rate variability (HRV) are used to estimate cardiac autonomic tone and disease risk in multiethnic populations, the genetic epidemiology of HRV in Hispanics/Latinos has not been characterized.
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nucleotide polymorphisms (SNPs), accounting for relatedness and adjusting for age, sex, study site, and ancestry. Cohort-specific estimates were combined using fixed-effects, inverse-variance meta-analysis. We investigated replication for select SNPs exceeding genome-wide (P ,5 ! 10 -8
) or suggestive (P ,10 -6
Introduction
Elevated resting heart rate (HR) is associated with various cardiovascular diseases, including hypertension, 1 acute myocardial infarction, 2, 3 and sudden cardiac death. 4 Even at rest, HR fluctuates cyclically because it is autonomically influenced by baroreflex tone, vagal outflow, neurohumoral rhythms, emotion, and other factors. 5 Cyclical HR fluctuation-termed heart rate variability (HRV)-is measured by time-and frequency-domain ECG metrics. 5 The relevance of these metrics for predicting morbidity and mortality independent of HR is well recognized.
Although HR and HRV have been used to estimate cardiac autonomic tone and disease risk in multiethnic populations, their genetic characterization remains incomplete despite substantial heritability. 6, 7 The only HRV genomewide association study (GWAS) reported to date was small (n 5 747 related individuals) and used a lenient threshold for statistical significance (P ,10 -3 ). 8 Furthermore, because HR GWAS have been conducted in European ancestry, 9 African-American, 10 and Asian 11 populations, the relevance of the identified loci to other populations remains unknown. Cardiovascular genetics may be particularly important for Hispanics/Latinos 12,13 because of their disproportionate burden of cardiac problems. Failure to extend GWAS analyses to diverse populations can reduce their global relevance and represent missed opportunities for discoveries and biologic insights. 14 We report the first GWAS of HR and HRV in Hispanic/Latino populations, providing new information about cardiac autonomic phenotypes in an understudied population.
Methods

HR and HRV
Standard, 12-lead ECGs were digitally recorded from resting, supine, or semirecumbent participants using comparable procedures across cohorts (see Supplemental Methods).
Genotyping
The genotyping platforms and algorithms, single nucleotide polymorphism (SNP) inclusion criteria, quality control, and imputation software are given in Supplementary Table S1 . Imputation was based on the 1000 Genomes phase 1 reference panel. 15 We tested only SNPs and no insertions/deletions. ). P ,10 -6 was considered suggestive. Significant and suggestive loci were assessed in phase 2 only if the minor allele frequency was .1% and the SNP represented a novel locus. We attempted replication separately in African-American and European ancestry cohorts. No independent Hispanic/ Latino cohorts were available. The P value threshold for replicating the 5 HRV SNPs was 0.05/10 5 0.005 (5 SNPs evaluated in African-American and European ancestry-10 hypothesis tests). Similarly, the P value threshold for replicating the 2 HR SNPs was 0.05/4 5 0.0125. Phase 2 used 1-sided P values.
Statistical analysis
We analyzed natural log of RMSSD and SDNN and untransformed HR. Analysis models adjusted for age, sex, body mass index (HR only), and appropriate study-specific covariates (e.g., principal components of ancestry; see Supplemental Methods). HCHS/SOL used mixed models accounting for genetic relatedness among participants and the study's complex sampling design. 17 We investigated genomic inflation using l GC and quantile-quantile plots of P values. Associated loci were visualized using LocusZoom. 18 Metaanalysis results are available on dbGaP (https://www.ncbi. nlm.nih.gov/gap; accession number phs000930).
Participants were excluded from analysis for atrial fibrillation, heart failure, angina, pacemaker implantation, ectopic beats, poor-quality ECG, too few intervals for calculating HRV, HR ,40 or HR .120, or use of tricyclic antidepressant or antiarrhythmic medications. HR analyses also excluded participants taking beta-blockers. Jackson Heart Study (phase 2 cohort) also excluded participants taking digoxin or anticholinergic medications.
SNPs were excluded from phase 1 analysis if the effective count of the minor allele was ,30 or imputation quality was poor (RSQ 0.3). Effective count was defined as 2*MAF*(1 -MAF)*n*oevar, where oevar measures imputation quality.
We examined whether SNP associations with HR from GWAS in European ancestry generalize to Hispanics/ Latinos. 9 The approach summarizes the evidence with an r value and rejects the generalization null hypothesis for r ,0.05, controlling the false discovery rate at 5%. 19 We further investigated generalization with a figure comparing reported associations to Hispanic/Latino results.
We interrogated replicated loci to identify potentially causal variants. In brief, we assessed whether variants lie within putative regulatory regions identified from ChIP-Seq (chromatin immunoprecipitation followed by sequencing) signals (see Supplemental Methods). We prioritized SNPs within a putative promoter or enhancer that overlapped with a DNaseI hypersensitive site. To hypothesize likely modes of action for these potentially causal variants, we report expression quantitative trait locus (eQTL) targets and/or motifs disrupted by prioritized variants.
Results
The discovery study included 13,767 Hispanics/Latinos from 3 cohorts (13,184 for HR), with HCHS/SOL contributing 84% of participants. Phase 2 included a European ancestry cohort (4,730 participants for HRV traits; 7,073 for HR; females only) and African-American ancestry cohorts (2,908 for HRV traits and 4,771 for HR). Tables 1 and 2 describe the cohorts contributing data to either phase.
Genome-wide association analysis
Meta-analyses of the 3 phase 1 discovery cohorts yielded l GC values of 1.00, 1.00, and 1.01 for RMSSD, SDNN, and HR, respectively (see Supplementary Table S2) . 20 These indices and quantile-quantile plots of P values raised no concerns for genomic inflation ( Figure 1 ). HR analysis yielded 1 genome-wide significant locus on chromosome 14. All 3 traits yielded suggestive loci ( Figure 1 ). We selected 5 HRV SNPs and 2 HR SNPs for phase 2 (Table 3 and Supplementary  Table S3 ). We did not select the genome-wide significant SNP for HR because it overlaps a recognized HR locus. 9 Both genome-wide significant HRV loci replicated in the European ancestry sample (Table 3 ; replication P ,.005). Neither locus was statistically significant in the phase 2 African-American sample, in which power was lower. None of the 3 suggestive HRV loci was statistically significant in phase 2. Of these 3 SNPs, 2 had good imputation quality in phase 2 data, and 1 had modest imputation quality (see Supplementary Table S4) .
Of the 2 suggestive HR SNPs, rs236352 on chromosome 6 was significantly associated with HR in the AfricanAmerican phase 2 sample (P ,.0125). The other suggestive HR SNP (rs17180489 on chromosome 14) was not significantly associated with HR in either phase 2 cohort. Variant rs17180489 had good imputation quality in phase 1 data but only modest quality in phase 2 (see Supplementary  Table S4) .
Figures 2 through 4 show regional association plots for the 3 SNPs that replicated in phase 2. Supplementary Figures S1 through S7 are plots for all selected SNPs. Figure 5 summarizes results for the 7 SNPs analyzed in both phases of the study for comparisons of effect sizes across ancestries. The 2 replicated HRV SNPs explained 0.91% and 0.72% of the variability of RMSSD and SDNN, respectively, in HCHS/SOL. The chromosome 6 SNP explained 0.15% of the variability of HR, and 1.17% when combined with the previously reported 21 HR SNPs. 9 We investigated associations of 4 candidate SNPs in genes ADBR2 and ADBR1 (see Supplementary Table S5) . Genome-wide summary data from this investigation are publically available to support future genetic investigations.
21 Figure 1 Manhattan and quantile-quantile plots for the meta-analyzed associations in Hispanics/Latinos for phenotypes RMSSD (A), SDNN (B), and HR (C). HR 5 heart rate; RMSSD 5 root mean squared difference in successive, normal-to-normal interbeat intervals; SDNN 5 standard deviation of normal-to-normal interbeat intervals.
Generalization analysis
We evaluated genome-wide significant loci reported in a previous GWAS of HR in European ancestry populations (N z 181,000) for generalization to Hispanic/Latino populations. Eleven of the 21 reported HR SNPs generalized (r ,0.05), with effects similar to those in the original report ( Figure 6 ). Confidence bounds for 9 of the 10 remaining SNPs show that the summary results for Hispanics/Latinos are consistent with effects observed in the European ancestry study, supporting the interpretation that the association discovered in European ancestry cohorts generalizes to Hispanics/Latinos. For a single SNP, rs2067615, the direction Two SNPs (*) were genome-wide significant in the Hispanic/Latino meta-analysis; all others were suggestive. The significance threshold for replication analysis is 0.005 for HRV SNPs and 0.0125 for HR SNPs. Bold P values indicate replication. The effect allele is the allele associated with higher trait values in phase 1. Figure 4 compares effect estimates across the 3 ancestry groups; Supplementary of the effect estimate in Hispanics/Latinos was opposite to that in the European ancestry study. Generalization analysis for this SNP is inconclusive due to wide confidence bounds. There is no comparable published GWAS of HRV for similar generalization analyses.
Discussion
There is growing attention to the lack of diversity in GWAS, 14, 22 which reduces the relevance of medical genomics globally and results in missed opportunities to leverage diversity to improve biologic understanding. There are fewer extensively phenotyped epidemiologic cohorts of non-Europeans; investigators must be resourceful in addressing the lack of diversity in GWAS. Therefore, we used 3 well-characterized Hispanic/Latino cohorts, with independent replication in European ancestry and African-American cohorts. We found novel associations between SNPs and HR or HRV, despite modest sample sizes. The findings are the first of their kind in Hispanics/Latinos and provide insight into the biologic mechanisms underlying SDNN, RMSSD, and HR.
At the chromosome 19 locus, the lead SDNN SNP (rs12982903) is in linkage disequilibrium with several potentially causal variants (r 2 0.8 in HCHS/SOL), including (1) rs12980262; (2) rs12974440; (3) rs12974991; (4) rs12975210; and (5) rs17271904 (see Supplementary  Figure 8 ). Variant rs12980262 is a missense alteration (g.5893047 G.A; c.557 C.T; p.Ala186Val) located in the last exon of NDUFA11 (NADH:ubiquinone oxidoreductase subunit A11). The altered protein is an isoform of a subunit of the membrane-bound mitochondrial complex I (NADHubiquinol reductase in the electron transport chain). Furthermore, ChIP-Seq data suggest that this SNP lies within a putative enhancer active in the fetal heart, right ventricle, and right atrium (home of the sinoatrial node) or pacemaker. Thus, variant rs12980262 may influence HRV through altered mitochondrial electron transport and/or gene regulation.
Noncoding SNPs (2) through (5) lie within putative enhancers and are active in various cardiac tissues; they may also have regulatory roles. In particular, rs12974440, rs12974991, and rs12975210 overlap with a DNaseI hypersensitive site in several heart tissues and have been reported as eQTLs for downstream genes RANBP3 (in whole blood) and CAPS (in whole blood and brain). In this context, CAPS is a potentially interesting enhancer target because it encodes a protein (calcyphosine) that binds calcium (Ca 21 ) and appears to be up-regulated by cAMP and thyroidstimulating hormone in the thyroid. 23 Although the exact function of calcyphosine remains unclear, thyroid effects on the heart are well recognized, 24 and the inward flow of Ca 21 through T-type Ca 21 channels (i Ca ) accelerates the autonomically controlled rate of phase 4 depolarization (and therefore discharge) of sinoatrial pacemaker cells in the right atrium. 25 In addition to using epigenetic datasets in cardiac tissues, we examined data from neuronal progenitor cells. These progenitors give rise to tissues involved in the control of HR and its variability by the central and peripheral autonomic nervous systems. Three noncoding variants lie within putative enhancers in neuronal progenitor cells: rs17271904 (on chromosome 19; see Supplementary Figure 8 ) and variants rs17287293 and rs11047543 in high LD with the lead RMSSD SNP (rs4963772 on chromosome 12). These variants may influence HR via central and/or peripheral autonomic nervous pathways. Moreover, KNOP1P1, 20 kb upstream of rs4963772, has been associated with HR 9, 26 and PR interval duration. 27, 28 The chromosome 6 HR SNP is within 200 kb of a locus that was suggestive in the large European ancestry HR GWAS (see Supplemental Table 5 in den Hoed et al   9 ). The gene closest to our lead SNP, PPIL1 (peptidylprolyl isomerase like 1), is proximal to a well-characterized QRS locus. [29] [30] [31] [32] Noncoding lead HR SNP rs236352 and its proxy rs236349 are likely functionally relevant in cardiac tissues (see Supplementary Figure 8 ). Variant rs236352 lies within a predicted cardiac superenhancer. 33, 34 The putative superenhancer overlaps a DNaseI hypersensitive site in cardiac tissues, ChIP-Seq peaks of RNA polymerase II, subunits of cohesion complexes (e.g., SMC3), and chromatin regulators (e.g., EP300), which are known to associate with superenhancers. 33, 35 Plausible right atrial gene targets of the superenhancer that contains rs236352 are its eQTL targets, CPNE5, which encodes a Ca 21 -dependent, phospholipid-binding protein, and PPIL1. Both are expressed in the right atrium, although neither gene has been identified as an eQTL in cardiac tissue. Interestingly, lead SNP rs236352 is predicted to disrupt the DNA binding motif of a T-box transcription factor that regulates CPNE5 expression. 36 Moreover, a short stretch of unannotated RNA overlapping the CPNE5 promoter is expressed differentially in the right (vs left) atrium, suggesting that the RNA may have a functional role in the right atrium. For example, if this unannotated RNA is an enhancer RNA associated with the superenhancer, then it could have a regulatory role in the right atrium. 37 The mechanisms by which these replicated and epigenetically well characterized HR and HRV loci may exert effects in the right atrium are biologically plausible. However, functional evaluation is needed to confirm the postulated underlying mechanisms. Clinical implications remain unclear. Moreover, associations for the lead SNP at the chromosome 19 and 12 loci were not statistically significant in the phase 2 African-American sample. For the RMSSD-rs4963772 association, this can be explained by the lower replication sample size, lower minor allele frequency, and therefore lower power for detecting association with this phenotype measured with error. Although the extent of measurement error is somewhat lower for RMSSD than SDNN and in studies with 30-vs 10-second ECG recordings (MESA vs HCHS/SOL and WHI), the same can reasonably be said about the SDNN-rs12982903 association, for which low imputation quality may have further reduced power.
Importantly, HRV and SNP measurement error should reduce statistical power but not introduce bias.
Because the European cohort in phase 2 included only females, HRV-SNP associations were not replicated in males. However, these SNPs were genome-wide significant in phase 1. There was no significant evidence that sex modifies the associations in the largest phase 1 cohort, HCHS/ SOL (P ..05). However, the association signal of SNP rs4963772 (chromosome 12) was stronger in females than males in sex-stratified analyses.
Our GWAS discovered and replicated a novel HR-associated locus on chromosome 6. We are the first to detect this association, even though HR was analyzed in a European ancestry GWAS 6 times larger. Possible reasons include chance, geneenvironment interaction, and population-specific variation.
Conclusion
HRV is an understudied phenotype, and the current finding of 2 genetic associations represents an advance in HRV genetics. In addition, we discovered a novel genetic association with HR, which replicated in African-Americans. Functional annotation analysis revealed plausible mechanisms for these associations. This novel discovery of genetic association for a well-studied phenotype, HR, argues for the importance of efforts to expand genetic association studies to populations of diverse ancestry. 
